Literature DB >> 11027804

Immunization with recombinant LD1 antigens protects against experimental leishmaniasis.

V S Dole1, V S Raj, A Ghosh, R Madhubala, P J Myler, K D Stuart.   

Abstract

The genes, ORFF and BT1 (previously ORFG), are part of the multigenic LD1 locus on chromosome 35 which is frequently amplified in Leishmania. BT1 encodes a biopterin transporter, while the function of the ORFF gene product is unknown, but it is localized to the nucleus. We show here that immunization of mice with recombinant ORFF and BT1 proteins, individually, or in combination, conferred partial protection against challenge with Leishmania donovani. Protection correlated with the production of antigen-specific antibodies and in vitro splenocyte proliferation. Thus, these antigens can be potential vaccine candidates against visceral leishmaniasis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11027804     DOI： 10.1016/s0264-410x(00)00207-3

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination.

Authors:  Barbara Papadopoulou; Gaétan Roy; Marie Breton; Christoph Kündig; Carole Dumas; Isabelle Fillion; Ajay K Singh; Martin Olivier; Marc Ouellette
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

4.  Development of the Antileishmanial Vaccine.

Authors:  Sunil Kumar; Shubhranshu Zutshi; Mukesh Kumar Jha; Prashant Chauhan; Bhaskar Saha
Journal:  Methods Mol Biol       Date:  2022

5.  Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Authors:  Rhea N Coler; Yasir A W Skeiky; Karen Bernards; Kay Greeson; Darrick Carter; Charisa D Cornellison; Farrokh Modabber; Antonio Campos-Neto; Steven G Reed
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

6.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

7.  A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs.

Authors:  Rodolfo Cordeiro Giunchetti; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho; Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Wendel Coura-Vital; Raquel Tropia de Abreu; Luiz Cosme Cotta Malaquias; Nelder Figueiredo Gontijo; Cláudia Brodskyn; Camila Indiani de Oliveira; Dirceu Joaquim Costa; Marta de Lana; Alexandre Barbosa Reis
Journal:  Vaccine       Date:  2007-12-17       Impact factor: 3.641

8.  Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs.

Authors:  Rodolfo Cordeiro Giunchetti; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho; Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Juliana Vitoriano de Souza; Nádia das Dores Moreira; Luiz Cosme Cotta Malaquias; Luciana Lisboa Mota e Castro; Marta de Lana; Alexandre Barbosa Reis
Journal:  Vaccine       Date:  2007-08-24       Impact factor: 3.641

9.  Vaccination in Leishmaniasis: A Review Article.

Authors:  Latifeh Abdellahi; Fariba Iraji; Anahita Mahmoudabadi; Seyed Hossein Hejazi
Journal:  Iran Biomed J       Date:  2022-01-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.